Drugs / DS-2325a
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05583669 | Nov 2022 → May 2023 | Netherton syndrome | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT05388903 | Jun 2022 → Jan 2023 | Netherton syndrome | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05979831 | Sep 2023 → Jan 2025 | Netherton syndrome | Daiichi Sankyo | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-2325a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05583669 ↗ |
| Action | Inhibit | “DS-2325a, a specific and potent inhibitor of kallikrein 5” NCT05388903 ↗ |
| Route | Subcutaneous | “Subcutaneous injection (starting dose 30 mg)” NCT05388903 ↗ |